Australian pharmaceutical firm Hatchtech has appointment Timothy Waugh as chief executive.
Waugh has worked in the pharmaceutical industry for 27 years and has spent the last 10 years with Roche in the US as a divisional vice president.
Paul Kelly, Hatchtech’s chairman, said: ‘Tim’s skill set and extensive experience will be a strong addition and complement those existing in the company. The Board is confident this management team will serve us well as we take the company into the next stage of developing and commercialising DeOvo for the global marketplace.’
DeOvo is a topical formulation of a known metalloprotease inhibitor and offer the potential for a head lice control treatment that requires only one application.
Waugh said he looks forward to working with Hatchtech’s Board and management team as it review the results of the Phase IIb study and plan for the next stages of its clinical development.
Waugh will join the Board of Hatchtech and will be based in New Jersey, US.
Hatchtech appoints Tim Waugh as ceo
Formerly with Roche in the US as a divisional vice president
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Packaging
Cloud labelling and serialisation: the new frontline of traceability in drug delivery
As drug delivery evolves to accommodate a new wave of data-driven innovation, the need for traceability and compliance throughout the supply chain is paramount. Innovative cloud-based solutions enable pharmaceutical companies to navigate these demands with confidence
Manufacturing
Sharp boosts autoinjector and pen assembly line capability with $20m investment in Pennsylvania facility
The money will boost its autoinjector and pen assembly, labelling and packaging lines across various therapeutic areas at its facility in Macungie, meeting the rising demand for injectables